Skip to main content

Table 3 Summary of findings and certainty of evidence for efficacy

From: Efficacy and safety of mesenchymal stem cells in the treatment of systemic sclerosis: a systematic review and meta-analysis

 

Summary of findings

Certainty of evidence

Certainty of evidence

No of participants (No of trials)

Mean difference (95% CI)

Study design

Inconsistency

Imprecision

Small study effects

mRSS

3 m

22 (3)

4.11 (2.19 to 6.02)

Downgraded*

Not downgraded

Not downgraded

Not downgraded

Moderate

6 m

52 (5)

5.09 (3.38 to 6.81)

Downgraded*

Not downgraded

Not downgraded

Not downgraded

Moderate

12 m

19 (2)

6.49 (4.61 to 8.37)

Downgraded*

Not downgraded

Not downgraded

Not downgraded

Moderate

mRSS

SVF

30 (2)

4.65 (0.74 to 8.57)

Downgraded*

Not downgraded

Not downgraded

Not downgraded

Moderate

UC-MSCs

19 (2)

5.08 (3.10 to 7.05)

Downgraded*

Not downgraded

Not downgraded

Not downgraded

Moderate

BMSCs

3 (1)

6.70 (− 0.22 to 13.62)

Downgraded*

Not downgraded

Not downgraded

Downgradedc

Low

RCS

6 m

30 (2)

1.80(− 3.38 to 6.99)

Downgraded*

Downgradeda

Not downgraded

Not downgraded

Low

DU

6 m

36 (4)

21.10 (3.63 to 122.56)

Downgraded*

Not downgraded

Downgradedb

Downgradedc

Very low

VAS

6 m

92 (3)

7.58 (0.55 to 14.60)

Downgraded*

Downgradeda

Not downgraded

Downgradedc

Very low

MHISS

12 m

69 (2)

5.52 (2.41 to 8.62)

Downgraded*

Downgradeda

Not downgraded

Not downgraded

Low

CHFS

6 m

30 (2)

9.05 (− 27.01 to 45.11)

Downgraded*

Downgradeda

Downgradedb

Downgradedc

Very low

  1. mRSS, modified Rodnan skin score; SVF, stromal vascular fraction; UC-MSCs, umbilical cord mesenchymal stem cells; BMSCs, bone marrow-derived mesenchymal stem cells; RCS, Raynaud’s condition score; DU, digital ulcer; VAS, visual analogue scale; CHFS, cochin hand function scale score; MHISS, mouth handicap in systemic sclerosis scale; m, month
  2. *Downgraded by one level because > 25% of participants in this comparison were from studies at high risk of bias
  3. aDowngraded by one level because heterogeneity (I2) > 50%
  4. bDowngraded by one level because the limits of the 95% confidence interval were 20 points different to smallest worthwhile effect
  5. cDowngraded by one level owing to small study bias